Drug
Rfviii FS KG
Rfviii FS KG: highest development phase Post-Market, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week NCT00632814 | Post-Market | Hemophilia A |
Latest
No recent events.
Follow Rfviii FS KG on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.